We have signed an evaluation agreement with Thyrocare, a large Indian network of diagnostic labs. They will evaluate our tuberculosis diagnostic in the coming year.
Clemedi conducted interviews with key-opinion leaders to validate the product-market fit of current and future products. Also, Niko attended three (virtual) conferences, South Summit, Wolf Summit and DxPx Europe. In total we got 19 interactions to follow-up with.
Clemedi has been invited to pitch at the Roche Diagnostics internal startup day. It was a fun event, where we could get an insight on how such a large company operates.
Our new user interface is connected to our backend and ready to be tested by user. It is deployed here: http://tuberculini.clemedi.com
Pauline is trained on the use of our sequencer and all aspects of our test and will start generating important data in the first weeks of the new year.
The team has started fundraising of the next financing round, expected to close in the second half of this year.
To close this report, we would like to wish everybody a happy new year full of success. Clemedi is excited about 2022 as we expect a lot of good things to happen.